| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.3 | 4e-08 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.33 | 7e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.3 | 2e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 6e-06 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.22 | 6e-05 |